CR9207A - Emplasto transdermico con ligandos especificos de protegesterona a (prasl) como principio activo - Google Patents

Emplasto transdermico con ligandos especificos de protegesterona a (prasl) como principio activo

Info

Publication number
CR9207A
CR9207A CR9207A CR9207A CR9207A CR 9207 A CR9207 A CR 9207A CR 9207 A CR9207 A CR 9207A CR 9207 A CR9207 A CR 9207A CR 9207 A CR9207 A CR 9207A
Authority
CR
Costa Rica
Prior art keywords
protegesterone
prasl
transdermal
environment
active principle
Prior art date
Application number
CR9207A
Other languages
English (en)
Inventor
Hans-Peter Podhaisky
Stefan Bracht
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9207A publication Critical patent/CR9207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion trata sobre un metodo para la determinacion de los constituyentes y sus impurezas en una mezcla coloreada de desechos en la fabricacion de vidrio.La formulacion de un lote de vidrio es ajustada basada en las caracteristicas medidas de un lote de mezcla coloreada de desecho, mas especificamente, ciertos preferentes en la presente invencion incluyen las etapas de alimentar cantidades de una mezcla coloreada de desecho recoletando al menos una mezcla de la muestra coloreada de desecho
CR9207A 2004-12-20 2007-06-25 Emplasto transdermico con ligandos especificos de protegesterona a (prasl) como principio activo CR9207A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004062182A DE102004062182B4 (de) 2004-12-20 2004-12-20 Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff

Publications (1)

Publication Number Publication Date
CR9207A true CR9207A (es) 2007-11-23

Family

ID=35559357

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9207A CR9207A (es) 2004-12-20 2007-06-25 Emplasto transdermico con ligandos especificos de protegesterona a (prasl) como principio activo

Country Status (20)

Country Link
EP (1) EP1671626A1 (es)
JP (1) JP2008524144A (es)
KR (1) KR20070089241A (es)
CN (1) CN101102754A (es)
AR (1) AR052168A1 (es)
AU (1) AU2005318548A1 (es)
BR (1) BRPI0519143A2 (es)
CA (1) CA2591076A1 (es)
CR (1) CR9207A (es)
DE (1) DE102004062182B4 (es)
EA (1) EA200701222A1 (es)
IL (1) IL183935A0 (es)
MX (1) MX2007007418A (es)
NO (1) NO20073768L (es)
PA (1) PA8657401A1 (es)
PE (1) PE20060841A1 (es)
TW (1) TW200633732A (es)
UY (1) UY29263A1 (es)
WO (1) WO2006066788A1 (es)
ZA (1) ZA200705991B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589542A (en) * 2008-05-30 2012-10-26 Mylan Inc Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
CN103893189B (zh) * 2012-12-26 2019-04-23 江苏康倍得药业股份有限公司 含雌二醇的药物组合物及其制备与应用
WO2020230760A1 (ja) * 2019-05-13 2020-11-19 東洋紡株式会社 フィルター用濾材およびフィルター

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
DE4309830C1 (de) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
DE19830649C2 (de) * 1998-07-09 2003-04-10 Lohmann Therapie Syst Lts Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DK1482925T3 (da) * 2002-03-11 2007-05-14 Bayer Schering Pharma Ag 5- (2-hydroxy-3 -'1 - (3-trifluormethylphenyl) cyclopropylpropionylamino) phtalid og relaterede forbindelser med progesteronreceptormoducerende aktivitet til anvendelse i fertilitetskontrol og hormonerstatningsterapi
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Also Published As

Publication number Publication date
DE102004062182B4 (de) 2007-06-06
EA200701222A1 (ru) 2007-12-28
UY29263A1 (es) 2006-06-30
EP1671626A1 (de) 2006-06-21
CN101102754A (zh) 2008-01-09
CA2591076A1 (en) 2006-06-29
DE102004062182A1 (de) 2006-06-29
MX2007007418A (es) 2007-08-17
BRPI0519143A2 (pt) 2008-12-30
AR052168A1 (es) 2007-03-07
TW200633732A (en) 2006-10-01
JP2008524144A (ja) 2008-07-10
WO2006066788A1 (de) 2006-06-29
KR20070089241A (ko) 2007-08-30
NO20073768L (no) 2007-07-19
AU2005318548A1 (en) 2006-06-29
IL183935A0 (en) 2007-10-31
ZA200705991B (en) 2009-01-28
PE20060841A1 (es) 2006-09-14
PA8657401A1 (es) 2006-07-03

Similar Documents

Publication Publication Date Title
CR9120A (es) Analisis y optimizacion de lotes para l afabricacion de vidrio
Ruan et al. Activation of the epithelial Na+ channel triggers prostaglandin E2 release and production required for embryo implantation
CR9207A (es) Emplasto transdermico con ligandos especificos de protegesterona a (prasl) como principio activo
AR051523A1 (es) Metodo para medir la resistencia o sensibilidad a docetaxel
UY29149A1 (es) Tiazolil-dihidro-indazoles
BRPI0517143A (pt) método de resfriamento para o seletivo rompimento de células ricas em lipìdeo controlado e uso deste método; sistemas para prover o dispositivo de realimentação e a informação de realimentação em conexão com o seletivo rompimento das células ricas em lipìdeo, bem como, a execução do método de tratamento cosmético
CR8529A (es) Nueva forma cristalina v de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contiene
CR10937A (es) Inhibidores de cinasa mapk/erk
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
ECSP088590A (es) Derivados de aminoácido multicíclicos y sus métodos de uso
BRPI0910368B8 (pt) uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores
BRPI0507683A (pt) dose unitária com liberação de formulação farmacêutica com liberação controlada, processo para sua preparação, bem como uso de um copolìmero de poli(acrilato de etila, metacrilato de metila) neutro
BR112012015428A2 (pt) composições de cuidado oral para uso com um dispositivo de luz oral
AR064067A1 (es) Un metodo y dispositivo de navegacion para visulaizacion de posicion en forma de texto legible
WO2007127327A3 (en) Nanopore sensor system
ECSP12012037A (es) Composiciones oftálmicas no irritantes de iodopovidona
CL2011002905A1 (es) Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad.
BR112018006045A2 (pt) análise de marcador de massa para células raras e moléculas isentas de células
BR112019008287A2 (pt) salto em frequência para transmissões de servirço multicast para dispositivos banda estreita
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
PE20211214A1 (es) Variantes de pertuzumab y su evaluacion
BR112015026601A2 (pt) método para um ensaio de triagem de fármaco à base de células e o uso do mesmo
CO2023005373A2 (es) Proteínas f de hmpv estabilizadas por prefusión
UY31700A (es) Tiazolil-dihidro-indazoles
AR071681A1 (es) Formulaciones de alimentos para animales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)